Key result
The premounted beStent-Artist coronary stent demonstrated favorable immediate results with no adverse events at 30 days and an 18.5% target vessel revascularization rate at 6 months.
Why the study?
Does the beStent-Artist coronary stent provide favorable acute angiographic and 6-month clinical outcomes in patients with coronary lesions?
Observational (n=40)
Does the beStent-Artist coronary stent provide favorable acute angiographic and 6-month clinical outcomes in patients with coronary lesions?
The beStent-Artist coronary stent demonstrated favorable acute angiographic success and safety at 30 days, though 18.5% of patients required target vessel revascularization at 6 months.
The beStent-Artist coronary stent is a newly developed, stainless steel coronary stent with a serpentine tubular design and terminal stent markers, premounted on a semicompliant balloon. During this pilot evaluation we aimed to test the acute clinical and angiographic results, short-term (30 days) and 6-month clinical results. A total of 57 stents were used to treat 43 lesions in 40 patients. Deployment strategy included predilatation, stent deployment, balloon repositioning to match the distal end of the balloon to the distal stent marker, and subsequent 12-14 atm postdilatation. There were two cases of stent dislodgment, but no procedural complications. In four cases, stent recrossing with another balloon was necessary. In two of these cases, distal dissections were observed and treated with another stent. The minimal lumen diameter (MLD) increased from 0.84+/0.52 mm at baseline to 2.7+/-0.62 mm at the end of the procedure (a corresponding decrease in diameter stenosis from 78.6 > 16.4 to 18.2+/-10.7%). The acute gain was 1.89+/-0.61mm. No adverse events occurred by 30 days. During six months, 7/40 (18.5%) of patients required target vessel revascularization due to in-stent restenosis. In summary, the premounted beStent-Artist can be delivered and deployed with favorable immediate results and high success rate with favorable long-term recurrent event rates.
No takes yet. Share an insight, caveat, or question.
Gruberg et al. (1999) conducted an observational in Coronary lesions (n=40). beStent-Artist coronary stent was evaluated on Target vessel revascularization at 6 months. The premounted beStent-Artist coronary stent demonstrated favorable immediate results with no adverse events at 30 days and an 18.5% target vessel revascularization rate at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: